scispace - formally typeset
A

Ali Salimi

Researcher at Baqiyatallah University of Medical Sciences

Publications -  21
Citations -  715

Ali Salimi is an academic researcher from Baqiyatallah University of Medical Sciences. The author has contributed to research in topics: Mesenchymal stem cell & Polycaprolactone. The author has an hindex of 14, co-authored 21 publications receiving 500 citations. Previous affiliations of Ali Salimi include Tarbiat Modares University.

Papers
More filters
Journal ArticleDOI

Targeting delivery of oxaliplatin with smart PEG-modified PAMAM G4 to colorectal cell line: In vitro studies

TL;DR: The anti-cancer efficacy of oxaliplatin was modulated using a nanocarrier system with enhanced targeting efficacy towards folic acid receptors (FAR) expressing colorectal cancer cells using PEG-PAMAM-FA-OX nano-complex as a final synthetic system.
Journal ArticleDOI

Nisin, a potent bacteriocin and anti-bacterial peptide, attenuates expression of metastatic genes in colorectal cancer cell lines.

TL;DR: Nisin could suppressed metastatic process via down-regulation of CEA, CEAM6, MMP2F, M MP9F genes, which play a role in the prevention local tumor invasion, metastasis and recurrence.
Journal ArticleDOI

Osteoblast differentiation of mesenchymal stem cells on modified PES-PEG electrospun fibrous composites loaded with Zn2SiO4 bioceramic nanoparticles

TL;DR: The results indicated that the combination of Zn2SiO4 nanoparticles and electrospun fibers is able to provide a new, suitable and more efficient matrix to support stem cells differentiation for bone tissue engineering applications.
Journal ArticleDOI

Generation of insulin-producing cells from human adipose-derived mesenchymal stem cells on PVA scaffold by optimized differentiation protocol.

TL;DR: This study demonstrated that the PVA nanofibrous scaffolds along with the optimized differentiation protocol with PRP can enhance the differentiation of IPCs from hADSCs, providing a new approach to the future pancreatic tissue engineering and beta cell replacement therapies for T1DM.